





Passport No :	LABORATORY TEST REF	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab Id : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL	Location :
Ref. ld :	Collected at : non SAWPL Collected on : 20-Feb-2023 08:53	Approved on : 20-Feb-2023 11:09 Status : Final
Ref. By :	Sample Type : EDTA Blood	Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Complete Blood Count

				ompiete blood count			
Test Hemoglobin	Colonimetric	Result 14.5	Unit g/dL		Biologica 13.0 - 16.5		terval
RBC Count	Electrical Impedance	4.79	millio	on/cmm	4.5 - 5.5		
Hematocrit	Calculated	43.3	%		40 - 49		
MCV	Derived	90.3	fL		83 - 101		
МСН	Calculated	30.2	pg		27.1 - 32.5	5	
мснс	Calculated	33.4	g/dL		32.5 - 36.7	7	
RDW CV	Calculated	13.60	%		11.6 - 14		
Total WBC and Differential Count							
WBC Count	SF Cube cell analysis	10570	/cmr	n	4000 - 100	000	
fferential Count					Absolute	Count	
Neutrophils	Microscopic	73	%	40 - 80	7716	/cmm	2000 - 6700
Lymphocytes	Microscopic	19	%	20 - 40	2008	/cmm	1100 - 3300
Eosinophils	Microscopic	02	%	1 - 6	211	/cmm	00 - 400
Monocytes	Microscopic	06	%	2 - 10	634	/cmm	200 - 700
Basophils	Microscopic	00	%	0-2	0	/cmm	0 - 100
Platelet Count	Electrical impedance	150000	/cmn	n	150000 - 4	10000	
MPV	Calculated H	14.00	fL		7.5 - 10.3		
eripheral Smear Ex	amination						

RBC Morphology Normochromic Normocytic

WBC Morphology WBCs Series Shows Normal Morphology

Platelets are adequate with normal morphology. Platelets Morphology

Parasites Malarial parasite is not detected.

Erythrocyte Sedimentation Rate

ESR 0 - 14 mm/1hr Capillary photometry

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

This is an Electronically Authenticated Report.

MD Path

Referred Test

Dr. Yash Shah

Page 1 of 19





Passport No :	LABORATORY TEST REI	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982 Ref. ld : Ref. By :	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL Collected on : 20-Feb-2023 08:53 Sample Type : EDTA Blood, Serum	Location : Approved on : 20-Feb-2023 13:33 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Blood Group

Test Result Unit Biological Ref. Interval

"A" ABO Type

Rh (D) Type Positive

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah MD Path

Page 2 of 19

This is an Electronically Authenticated Report.

Referred Test







Passport No :		LABORATORY TEST RE				
Patient Information		Sam	ple	Information		Client/Location Information
Name : Lyubochka Svetk	a	Lab ld	:	02232160XXXX	Client Name	: Sterling Accuris Buddy
Sex/Age : Male / 41 Y 0				20-Feb-2023 09:10	Location	:
	1-Feb-1982 (non SAWPL	Approved or	: 20-Feb-2023 11:29 Status : Final
Ref. ld :	Ι.	Collected on	_	20-Feb-2023 08:53	Printed On	: 28-Feb-2023 10:26
Ref. By :	1 :	Sample Type	=	Serum	Process At	: 1. NRL SAWPL Gujarat Ahmedabad Paldi

	Lipid Pro	file	
Test	Result	Unit	Biological Ref. Interval
Cholesterol Cholesterol oxidase – Peroxidase method	189.0	mg/dL	Desirable : <200 Borderline High : 200-239 High : >240
Triglyceride Ezymatic (Lipase/GK/GPO/POD)	H 168.0	mg/dL	Normal : <150 Borderline : 150-199 High : 200-499 Very High : >500
HDL Cholesterol	60.0	mg/dL	Low: <40.0 High: >60.0
Direct LDL Direct measured	H 100.39	mg/dL	Optimal: <100 Near to above Optimal: 100–129 Borderline High: 130-159 High: 160–189 Very High: =190
VLDL Calculated	33.60	mg/dL	15 - 35
CHOL/HDL Ratio	3.1		Up to 5.0
LDL/HDL Ratio	1.7		Up to 3.5

Q:l

Dr. Purvish Darji MD(Path)

Dr. Sanjeev Shah MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Dr. Yash Shah

Page 3 of 19







Passport No :	LABORATORY TEST REF	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-19	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPI	Location :
Ref. ld :	Collected at : non SAWPL Collected on : 20-Feb-2023 08:53	Approved on : 20-Feb-2023 11:45 Status : Final
Ref. By :	Sample Type : Fluoride plasma	Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Biochemistry

Test Result Unit Biological Ref. Interval Fasting Blood Sugar H 141.0 mg/dL 74 - 106

Q:l

Dr. Purvish Darji MD(Path)

Dr. Sanjeev Shah MD Path

Dr. Yash Shah MD Path

This is an Electronically Authenticated Report.

Page 4 of 19 # Referred Test







: 20-Feb-2023 11:33 Status :

Information

Scan QR co report authenticity

Location

mg/dL

Approved on

Passport No :	LABORATORY TEST REP	ORT
Patient Information	Sample Information	Client/Location
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
	Registration on: 20-Feb-2023 09:10	Location

Collected at

Collected on

: 20-Feb-2023 08:53 Printed On : 28-Feb-2023 10:26 Sample Type : EDTA Blood Ref. By : 1. NRL SAWPL Gujarat Ahmedabad Paldi Process At

: non SAWPL

HbA1c (Glycosylated Hemoglobin)

Test Result Unit Biological Ref. Interval	
HbA1c High Performance Liquid Chromatography H 7.10 % For Screening: Diabetes: >6.5% Pre-Diabetes: 5.7% - 6.4% Non-Diabetes: < 5.7% For Diabetic Patient: Poor Control: > 7.0 % Good Control: 6.0-7.0 %	1c erformance Liquid Chromatography

Explanation:-

- Total haemoglobin A1 c is continuously synthesized in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.
- The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose concentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels.
- The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days, HbA1c has been accepted as a measurement which reflects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding
- It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

157.07

HbA1c assay Interferences:

Mean Blood Glucose

: Male / 41 Y

Ref. Id

01-Feb-1982

Erroneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c (HbF) or differences in their glycation from that of HbA (HbS).

Reference: ADA Guideline 2023

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr.Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 5 of 19







Scan	QR	code	to	check	
De	nort	authe	-mt	lethy	

Pass	oort No :	LABORA	ATORY TEST REP	JRT	
	Patient Information	Samp	ole Information		Client/Location Information
Name	: Lyubochka Svetka	Lab ld	: 02232160XXXX	Client Name : Ste	erling Accuris Buddy
Sex/A	ge : Male / 41 Y 01-Feb-1982		1 : 20-Feb-2023 09:10	Location :	
Ref. ld			: 20-Feb-2023 08:53		-Feb-2023 11:38 Status : Final
Ref. B	y :	Sample Type	: Serum		-Feb-2023 10:26 NRL SAWPL Guiarat Ahmedabad Paldi

Thyroid Function Test

	,			
Test	Result	Unit	Biological Ref. Interval	_
T3 - Trijodothyronine	1.01	ng/mL	0.58 - 1.59	
T4 - Thyroxine	7.84	mg/mL	4.87 - 11.72	
TSH - Thyroid Stimulating Hormone	0.8199	microIU/mL	0.35 - 4.94	

тан	T3/FT3	T4/FT4	Suggested Interpretation for the Thyroid Function Tests Pattern
Within Range	Decreased	Within Range	 Isolated Low T3-offea seen in elderly & associated Non-Thyroidal illness. In elderly the drop in T3 level can be upto 25%
Raised	Within Range	Within Range	Isolated High TSH especially in the range of 4.7 to 15 mlU/ml is commonly associated with physiological 8 Biological TSH Variability. Subclinical Autoimmune Hypothyrioidism - Intermitted 14 therapy for hypothyrioidism Recovery phase after Non-Thyroidal illness
Raised	Decreased	Decreased	Chronic autsimmune Thyroiditis Post thyroidectomy, Post radiciocine Hypothyroid phase of transient thyroiditis
Raised or Within Range	Raised	Raised or Within range	Interforing antibodies to thyroid hormones (anti-TPO antibodies) intermittent T4 therapy or T4 overdose Drug interference-Amiodarone, Heperin, Beta blockers, steroids, anti-epileptics
Decreased	Raised or within Range	Raised or within Range	 Isolated Low TSH*- especially in the range of 0.1 to 0.4 offen seen in elderly & associated with Non-Thyroidal litness Subcrinical Hyperthyroidism Thyroxine Ingestion
Decreased	Decreased	Decreased	Central Hypothyroidism Non-Thyroidal illness Recent treatment for Hyporthyroidism (TSH remains suppressed)
Decreased	Raised	Plaised	Primary Hyperthyroldism (Graves disease), Maltinodular goltre Toxic nodule Transient thyroidilis-Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacuto, DeQuervain's) Gestational thyrotoxicosis with hyperemesis gravidarum
Decreased or within range	Reised	Within Range	- T3 toxicosis - Nen-Thyroidal illness

Q:l

Dr. Purvish Darji MD(Path)

Dr. Sanjeev Shah MD Path

Dr. Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 6 of 19





Printed On

Process At

Approved on : 20-Feb-2023 12:40 Status: Final

: 1. NRL SAWPL Gujarat Ahmedabad Paldi

: 28-Feb-2023 10:26



Scan QR code to check report authenticity

Passport No :	LABORATORY TEST REPORT		
Patient Information	Sample Information	Client/Location Information	
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy	
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on : 20-Feb-2023 09:10	Location :	

: 20-Feb-2023 08:53

Biochemistry

Collected on

Sample Type : Urine

Test	Result	Unit	Biological Ref. Interval	•
Microalbumin (per urine volume)	10.50	mg/L	< 16.7	

In random urine specimens, normal urinary albumin excretion is below 17 mg/g creatinine for males and below 25 mg/g creatinine for females.(3) Microalbuminuria is defined as an albumin:creatinine ratio of 17 to 299 for males and 25 to 299 for females.

A ratio of albumin:creatinine of 300 or higher is indicative of overt proteinuria.

Due to biologic variability, positive results should be confirmed by a second, first-morning random or 24-hour timed urine specimen. If there is discrepancy, a third specimen is recommended. When 2 out of 3 results are in the microalbuminuria range, this is evidence for incipient nephropathy and warrants increased efforts at glucose control, blood pressure control, and institution of therapy with an angiotensin-converting-enzyme (ACE) inhibitor (if the patient can tolerate it).

Reference:

Ref. Id

Ref. By

- Bennett PH, Haffner S, Kasiske BL, et al: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations
 to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National
 Kidney Foundation. Am J Kidney Dis 1995;25:107-112
- Krolewski AS, Laffel LM, Krolewski M, et al: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251-1255
- Zelmanovitz T, Gross JL, Oliveira JR, et al: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997;20:518-519

F-6

Dr. Purvish Darji MD(Path) Dr. Sanjeev Shah MD Path Dr.Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 7 of 19







Passport	t No :	LABORA	١T	ORY TEST REF	PORT	
	Patient Information	Samp	ole	Information		Client/Location Information
Name	: Lyubochka Svetka	Lab ld	:	02232160XXXX	Client Nam	ne : Sterling Accuris Buddy
Sex/Age	: Male / 41 Y 01-Feb-1982	_	:	20-Feb-2023 09:10	Location	:
	: male / 4/ / 01-160-1602	Collected at	-	non SAWPL 20-Feb-2023 08:53	Approved	
Ref. By		Sample Type	:	Serum	Printed On Process A	. 20100 2020 10:20

	Protein		
Test	Result	Unit	Biological Ref. Interval
Total Protein Copper tartrate to colour complex	7.00	g/dL	6.3 - 8.2
Albumin Bromocresol Green Method	4.20	g/dL	3.5 - 5.0
Globulin Calculated	2.80	g/dL	2.3 - 3.5
A/G Ratio Calculated	1.50		1.3 - 1.7
	Bilirubi	n	
Total Bilirubin Azobiirubin chromophores	0.70	mg/dL	0.2 - 1.3
Conjugated Bilirubin	0.30	mg/dL	0.0 - 0.3
Unconjugated Bilirubin Cationic Mordant Binding	0.20	mg/dL	0.0 - 1.1
Delta Bilirubin	0.20	mg/dL	0.0 - 0.2

Q:l

Dr. Purvish Darji MD(Path)

Dr. Sanjeev Shah MD Path

Dr. Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 8 of 19







Passport No :	LABORATORY TEST REPORT			
Patient Information	Sample Information	Client/Location Information		
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy		
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on : 20-Feb-2023 09:10	Location :		
Ref. Id :	Collected at : non SAWPL Collected on : 20-Feb-2023 08:53	Approved on : 20-Feb-2023 11:29 Status: Final		
Ref. By :	Sample Type : Serum	Printed On : 28-Feb-2023 10:28 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi		

-	ron	ш	п	100

	non otaa.		
Test	Result	Unit	Biological Ref. Interval
Iron Pyndyl azo Dye	103.00	micro g/dL	49 - 181
Total Iron Binding Capacity (TIBC)	352.00		261 - 462
Transferrin Saturation	29.26	%	Children : >16 Adult : 20 - 50

Q:l

Dr. Purvish Darji MD(Path)

Dr. Sanjeev Shah MD Path

Dr. Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 9 of 19







Passport No :	LABORATORY TEST REP	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982 Ref. ld : Ref. By :	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL Collected on : 20-Feb-2023 08:53 Sample Type : Serum	Location : Approved on : 20-Feb-2023 11:38 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Immunoassay

Test Result Unit Biological Ref. Interval

Homocysteine, Serum
Chemiluminessence H 23.86 micromol/L 6.0 - 14.8

Summary and Uses:

- Total Hcy is a thiol-containing amino acid, produced by the intracellular demethylation of methionine to cysteine.
- Elevated levels of t Hcy may be used to exclude or confirm deficiencies of vitamin B12 or folate.
- It is recommended to test in patients using medications that interfere with folate status (methotrexate, antiepileptics), vegetarians without B12 supplementations, unexplained anemia, peripheral neuropathy or myleopathy, recurrent spontaneous abortions or infertility.
- Testing also recommended for patients 40 years of age with coronary artery disease to exclude homocystinuria.
- Elevations in tHcy levels have also been used as an independent risk factor of coronary or cerebral
 vascular disease. Treatment of moderate hyperhomocystinemia with folic acid supplementation for primary
 and secondary cardiovascular protection has met with inconsistent results and at present cannot be
 routinely recommended.

Limitations:

- The plasma must be seprated immediately on collection to avoid continuous synthesis of Hcy by red cells.
- Samples must be immediately stored on ice and serum centrifuged immediately before a complete clot is formed
- Certain drugs, such as anticonvulsants, methotrexate, or nitrous oxide, may interfere with the assay.
- Cigarette smoking and coffee consumption increase tHcy levels.
- Intraindividual variability is approximately 8%; it can be as much as 25% in patients with hyperhomocystinemia.
- Generally, a single measurement of tHcy is considered adequate.

P.c

Dr. Purvish Darji MD(Path) Dr. Sanjeev Shah MD Path Dr.Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 10 of 19







Passport No :	LABORATORY	LABORATORY TEST REPORT		
Patient Information	Sample Inform	nation Client/Location Information		
Name : Lyubochka Svetka	Lab ld : 0223	2160XXXX Client Name : Sterling Accuris Buddy		
	Registration on : 20-Fe Collected at : non S	AWPL Approved on : 20-Feb-2023 11:10 Status : Final		
Ref. ld : Ref. By :	Collected on : 20-Fe Sample Type : Serum	Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi		

Biochemistry

Test	Result	Unit	Biological Ref. Interval
Creatinine, Serum Creatinine Amidohydrolase	0.83	mg/dL	0.66 - 1.25
Urea Drease, Colorimetric	L 18.0	mg/dL	19.3 - 43.0
Blood Urea Nitrogen	L 8.41	mg/dL	9.0 - 20.0
Uric Acid Uncase	4.90	mg/dL	3.5 - 8.5
Calcium Arsenazo III	9.10	mg/dL	8.4 - 10.2
SGPT DV with P5P, IFCC	48.0	U/L	0 - 50
SGOT UV with PSP	27.0	U/L	17 - 59
	Electro	lytes	
Sodium (Na+) Direct- ISE	143.00	mmol/L	136 - 145
Potassium (K+) Direct-ISE	4.90	mmol/L	3.5 - 5.1
Chloride (CI-) Direct-ISE	105.0	mmol/L	98 - 107

Q:l

Dr. Purvish Darji MD(Path)

Dr. Sanjeev Shah MD Path

Dr. Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 11 of 19







Passport No :	LABORATORY TEST REPORT		
Patient Information	Sample Information	Client/Location Information	
Name : Lyubochka Svetka	Lab Id : 02232160XXXX	Client Name : Sterling Accuris Buddy	
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on: 20-Feb-2023 09:10	Location :	
		Approved on : 20-Feb-2023 12:33 Status : Final	
Ref. ld :	Collected on : 20-Feb-2023 08:53	Printed On : 28-Feb-2023 10:26	
Ref. By :	Sample Type : Serum	Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi	

Immunoassay

Test Result Unit Biological Ref. Interval

25(OH) Vitamin D

8.98

ng/mL

Deficiency: <10
Insufficiency: 10 - 30
Sufficiency: 30 - 100
Toxicity: >100

Vitamin D is a fat soluble vitamin and exists in two main forms as cholecalciferol(vitamin D3) which is synthesized in skin from 7-dehydrocholesterol in response to sunlight exposure & Ergocalciferol(vitamin D2) present mainly in dietary sources. Both cholecalciferol & Ergocalciferol are converted to 25(OH)vitamin D in liver.

Interpretation:

Increased In

- Vitamin D intoxication
- Excessive exposure to sunlight

Decreased In

- Malabsorption
- Steatorrhea
- Dietary osteomalacia, anticonvulsant osteomalacia
- Biliary and portal cirrhosis
- Thyrotoxicosis
- Pancreatic insufficiency
- Celiac disease
- Rickets
- Alzheimer disease

Limitations:

More recently, it has become clear that receptors for vitamin D are present in a wide variety of cells and that this hormone has biologic effects extending beyond the control of mineral metabolism. Vitamin D deficiency is not clear. Levels needed to prevent rickets and osteomalacia (15 ng/mL) are lower than those that dramatically suppress parathyroid hormone levels (20–30 ng/mL). In turn, those levels are lower than levels needed to optimize intestinal calcium absorption (34 ng/mL). Neuromuscular peak performance is associated with levels approximately 38 ng/mL. A recent study states that increasing mean baseline levels from 29 to 38 ng/mL was associated with a 50% lower risk for colon cancer and levels of 52 ng/mL with a 50% reduction in the incidence of breast cancer. It is recommended to have clinical correlation with serum 25(OH)vitamin D, serum calcium, serum PTH & serum alkaline phosphatase.

S)love

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr.Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 12 of 19







Passport No :	LABORATORY TEST REPORT			
Patient Information	Sample Information	Client/Location Information		
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy		
Sex/Age : Male / 41 Y	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL	Location :		
Ref. ld :	Collected at : non SAWPL Collected on : 20-Feb-2023 08:53	Approved on : 20-Feb-2023 12:04 Status : Final		
Ref. By :	Sample Type : Serum	Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi		

Immunoassay

Test Result Unit Biological Ref. Interval

Vitamin B12 L < 148 pg/mL 187 - 833

Vitamin B12 is essential in DNA synthesis, hematopoiesis, and CNS integrity.

Interpretation:

- Increased In : Chronic granulocytic leukemia , COPD and Chronic renal failure , Leukocytosis , Liver cell damage (hepatitis, cirrhosis) , Obesity and Severe CHF , Polycythemia vera , Protein malnutrition.
- Decreased In : Abnormalities of cobalamin transport or metabolism , Bacterial overgrowth , Crohn disease , Dietary deficiency (e.g. in vegetarians) , Diphyllobothrium (fish tapeworm) infestation , Gastric or small intestine surgery , Hypochlorhydria , Inflammatory bowel diseas , Intestinal malabsorption and Intrinsic factor deficiency

Limitations:

- Drugs such as chloral hydrate increase vitamin B12 levels. On the other hand, alcohol, aminosalicylic acid, anticonvulsants, ascorbic acid, cholestyramine, cimetidine, colchicines, metformin, neomycin, oral contraceptives, ranitidine, and triamterene decrease vitamin B12 levels.
- The evaluation of macrocytic anemia requires measurements of both vitamin B12 and folate levels; ideally they should be measured simultaneously.
- Specimen collection soon after blood transfusion can falsely increase vitamin B12 levels.
- Patients taking vitamin B12 supplementation may have misleading results.
- A normal serum concentration of B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for B12 deficiency at the
 cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered,
 even if serum B12 concentrations are normal.

Thote

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Dr.Yash Shah

Page 13 of 19







Passport No :	LABORATORY TEST REP	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPI	Location :
Ref. ld :	Collected at : non SAWPL Collected on : 20-Feb-2023 08:53	Approved on : 20-Feb-2023 11:38 Status : Final
Ref. By :	Sample Type : Serum	Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Immunoassay

Test	Result	Unit	Biological Ref. Interval
PSA-Prostate Specific Antigen, Total	0.573	ng/mL	0 - 4

PSA is a glycoprotein that is expresses by both normal and neoplastic prostate tissue and is prostate tissue specific and not prostate cancer specific. PSA is constantly expressed in nearly all prastate cancers, although its level of expression on a percell basis is lower than in normal prostate epithelium. The absolute value of serum PSA is useful for determining the extent of prostate cancer and assessing the response to prostate cancer treatment; its use as a screening method to detect prostate cancer is also common.

Interpretation

Increased in

- Prostate disease (Cancer, Prostatitis, Benign prostatic hyperplasia, Acute urinary retention)
- Manipulations (Cystoscopy, Needle biopsy, Radiation therapy, Indwelling catheter, Prostatic massage)
- Transurethral resection
- Prostatic ischemia

Decreased in

- Castration
- Prostatectomy
- Radiation therapy
- Ejaculation withi 24 48 hours
- 5-alpha-reductase inhibitor reduces PSA by 50% after 6 months in men without cancer

Limitations

- PSA has been recommended by the American Cancer Society for use in conjunction with a DRE for early detection of prostate cancer starting at the age of 50 years for men with at least 10 year life expectancy
- PSA levels that are measured repeatedly over time may vary because of biologic variability where the true PSA level in a given man is different on different measurements.
- A change in PSA of >30% in man with a PSA initially below 2.0 ng/mL was likely to indicate a true change beyond normal random variation.

P.C

Dr. Purvish Darji MD(Path) Dr. Sanjeev Shah MD Path Dr.Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 14 of 19





Passport No :	LABORATORY TEST REP	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL	Location : Approved on : 20-Feb-2023 12:06 Status : Final
Ref. ld : Ref. By :	Collected on : 20-Feb-2023 08:53 Sample Type : Serum	Approved on : 20-Feb-2023 12:06 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Immunoassay

Test Result Unit Biological Ref. Interval IgE H 492.30 IU/mL 0 - 87

IgE mediates allergic and hypersensitivity reactions. There is a significant overlap in total IgE between allergic and nonallergic individuals. Interpretation:

- Increased In
 - Atopic diseases
 - · Exogenous asthama in approximately 60% of patients
 - · Hay fever in approximately 30% of patients and Atopic eczema
 - Influenced by type of allergen, duration of stimulation. Presence of symptoms, and hyposensitization treatment
 - Parasitic diseases (e.g. ascariasis, visceral larva migrans, hookworm disease, schistosomiasis, Echinococcus infestation)
 - Monoclonal IgE myeloma
- Decreased In
 - Hereditary deficiencies
 - Acquired immunodeficiency
 - Ataxia-telangiectasis
 - Non-IgE myeloma

Limitations:

- A normal level of IgE in serum does not eliminate the possibility of allergic disease.
- Serum total IgE levels for the majority of individuals with IgE-mediated disease can be expected to be elevated compared to the reference range for healthy adults. However, not all allergic patients exhibit elevated serum total IgE levels.
- Since not all atopic reactions are IgE-mediated, a total IgE result in the reference range should always be interpreted in light of other clinical observations.
- Heterophilic antibodies in human serum can react with the immunoglobulins included in the assay components causing interference with in vitro immunoassays.

P.c

Dr. Purvish Darji MD(Path) Dr. Sanjeev Shah MD Path Dr.Yash Shah MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 15 of 19







Passport	No :	LABORA	١T	ORY TEST REF	PORT	
Р	Patient Information	Samp	ole	Information		Client/Location Information
Name	: Lyubochka Svetka	Lab ld	:	02232160XXXX	Client Name	: Sterling Accuris Buddy
Sex/Age	: Male / 41 Y 01-Feb-1982	_	:	20-Feb-2023 09:10	Location	:
Ref. ld	: male / 411	Collected at	:	non SAWPL 20-Feb-2023 08:53	Approved or	n : 20-Feb-2023 14:35 Status : Final
Ref. By	:	Sample Type	:	Serum	Printed On Process At	: 28-Feb-2023 10:26 : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Test	Result	Unit	Biological Ref. Interval
HIV I & II Ab/Ag with P24 Ag	0.070	S/Co	Non Reactive : <1.0 Reactive : >1.0
Interpretation	Non Reactive		
HBsAg Chemiluminescence	0.290	S/Co	Non Reactive : <1.0 Reactive: >1.0
Interpretation	Non Reactive		

- A NON REACTIVE result implies that no Anti HIV-1 or HIV -2 antibodies have been detected in the sample by this method. This means that either the patient has not been exposed to HIV-1 or HIV-2 infection or the sample has been tested during the "WINDOW PHASE" (before the development of detectable levels of antibodies).
- A PROVISIONALITY REACTIVE / BORDERLINE REACTIVE result suggests possibility of HIV-1 or/and HIV-2 infection. However these results must be verified by confirmatory WESTERN BLOT / HIV PCR method before declaring the patient positive for HIV-1 or HIV-2 infection. 2.
- Very high levels of IgM Antibodies or Anti-HLA ABC and DR Antibodies can give false positive reaction.

**Pre & Post test counselling for HIV testing is responsibility of reffering Physician.

Dr. Siddharth Thummar

Dr. Sanjeev Shah

This is an Electronically Authenticated Report.

Dr. Yash Shah MD Path

M.D. Pathology

MD Path

Referred Test

Page 16 of 19







Passport No :	LABORATORY TEST REP	ORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982 Ref. ld : Ref. By :	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL Collected on : 20-Feb-2023 08:53 Sample Type : EDTA Blood	Location : Approved on : 20-Feb-2023 14:16 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

HB Electrophoresis By HPLC Instrument Name: BIORAD VARIANT - II Haemoglobin Testing System

Test	Result	Unit	Biological Ref. Interval
Hb A	L 84.4	%	96.8 - 97.8
Hb A2	2.8	%	2.2 - 3.2
P2 Peak	5.5	%	
P3 Peak	5.2	%	
Foetal Hb	0.3	%	0.0 - 1.0
Interpretation	Negative for typical	l beta thalassemia trait.	

Interpretation:

- All results have to be correlated with age and history of blood transfusion if there is history of blood transfusion in last 3 months, repeat testing after 3 month from last date of transfusion is recommended.
- In case of haemoglobinopathy, parents or family studies and councelling is advised.
- This test detects beta thalassaemia and haemoglobinopathies, DNA analysis is recommended to rule out alpha thalassaemia and silent carriers.
- Linearity range of HbF is 1-40%, However, values in excess of the reportable range have been provided for ease of interpretation.
- Mild to moderate increase in fetal haemoglobiin can be seen in some acquired condition like pregnancy, megaloblastic anaemia, Throtoxicosis, Hypoxia, Chronic kidney disease, Recovering marrow, MDS, Aplastic anaemia, PNH, Medications (Hydrocyurea, Erythropoietin) ect.
- P3 window-Above 10% is often indicative of either denatured froms of hemoglobins or may suggest a possibility of abnormal haemoglobin variant. Hence, repeat analysis with fresh sample or DNA studies is advised.
- P2 Window-Above 10% is indicative of either glycated haemoglonin requiring correlation with diabetic staus or may suggest a possibility of abnormal haemoglobin variant further DNA studies for confirmation.

Jy.

Dr. Hardik Modi Hematopathologist (G-18097) Dr. Sanjeev Shah MD Path

MD Path

Page 17 of 19

This is an Electronically Authenticated Report.

Referred Test

Dr.Yash Shah

Bio-Rad CDM System VII Inst. #1. SN-13939



Patient Data

Sample ID:

022321600126

Patient ID:

Name:

Physician:

Sex: DOB:

Comments:

Analysis Data

Analysis Performed: 02/20/2023 13:56:59

Injection Number: 2575
Run Number: 95
Rack ID: 0001
Tube Number: 2

Report Generated: 02/20/2023 14:04:40


Operator ID:

Peak Name	Calibrated Area %	Area %	Retention Time (min)	Peak Area
Unknown		0.1	1.00	2400
F	0.3		1.08	8321
Unknown		1.6	1.18	44109
P2		5.5	1.30	148807
P3		5.2	1.72	139183
Ao		84.4	2.34	2277592
A2	2.8		3.64	76999

Total Area: 2,697,411

F Concentration = 0.3 % A2 Concentration = 2.8 %

Analysis comments:









Passport No :	LABORATORY TEST REF	PORT
Patient Information	Sample Information	Client/Location Information
Name : Lyubochka Svetka	Lab ld : 02232160XXXX	Client Name : Sterling Accuris Buddy
Sex/Age : Male / 41 Y 01-Feb-1982	Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL	Location :
Ref. ld : Ref. By :	Collected on : 20-Feb-2023 08:53 Sample Type : Urine	Approved on : 20-Feb-2023 11:12 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi

Test	Result	Unit	Biological Ref. Interval
nysical & Chemical (Dip strip) examinati	on_		
Colour	Pale Yellow		Pale Yellow
Clearity	Clear		Clear
pH Double indicator	6.0		4.6 - 8.0
Specific Gravity Polyelectrolyte based reaction	1.030		1.005 - 1.030
Urine Glucose GOD-POD	Present (+)		Absent
Urine Protein Protein error of indicators	Absent		Absent
Bilirubin Diazo reaction	Absent		Absent
Urobilinogen Modified Ehrlich reaction	Absent		Absent
Urine Ketone Nitroprusside	Absent		Absent
Nitrite Nitrite reaction	Absent		Absent
croscopic Examination			
Pus Cells	1-2		Absent
Red Cells	Nil	/hpf	0 - 2
Epithelial Cells	1-2	/hpf	
Casts	Absent	/hpf	Absent
Crystals	Absent	/hpf	Absent
Amorphous Material	Absent		

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah MD Path

This is an Electronically Authenticated Report.

MD Path

Dr. Yash Shah

Referred Test

Page 19 of 19